Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Share News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 2.00 (4.545%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 45.00
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cambridge Cognition swings to interim loss amid ballooning costs

Tue, 26th Sep 2023 12:00

(Alliance News) - Cambridge Cognition Holdings PLC on Tuesday reported an interim loss as costs increased significantly.

Cambridge Cognition is a Cambridgeshire, England-based company which develops and markets digital solutions to assess brain health.

The company said its pretax loss in the first half of 2023 totalled GBP3.4 million, swinging from a profit of GBP16,000 a year ago. Revenue rose 2.7% to GBP6.0 million from GBP5.9 million. Administrative expenses, however, ballooned by 89% to GBP8.4 million from GBP4.5 million.

"Trading conditions continued to be difficult in the first half of 2023, with some drug development companies cutting costs and others delaying clinical trials. Some companies providing solutions and services for clinical trials have reported declining performance in the period. While we increased the value of contracted orders from half-to-half, we did see some delays to contract awards that we anticipate will close in the second half of 2023 or in 2024," the firm said.

Cambridge Cognition said that the market had improved, with its contract order book rising to GBP19.9 million at the end of June from GBP17.6 million at the end of December.

Looking ahead, it expects 2023 revenue in line with analysts' consensus, of around GBP14 million. That would be 11% higher than GBP12.6 million in 2022, as the company is eyeing "a major step towards profitability in the second half of 2023".

Separately, the company announced that it received a GBP3 million term loan from Claret European Specialty Lending Company III Sarl, which specialises in providing growth capital to innovative businesses.

The loan has an annual 11.5% fixed interest rate and will be drawn down in full immediately, with a term of 36 months.

The company will use the loan to focus on executing its strategy of growth.

Cambridge Cognition shares fell 18% to 78.10 pence each on Tuesday morning in London.

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
15 Jul 2020 16:20

Cambridge Cognition joins Covid healthcare worker investigation

(Sharecast News) - Cambridge Cognition is collaborating with 4YouandMe and the Center for International Emergency Medical Services (CIEMS), it announced on Wednesday, to investigate the use of wearables and mobile phones to measure stress recovery in front line healthcare workers caring for Covid-19 positive patients in the United States.

Read more
15 Jul 2020 11:47

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

Read more
30 Jun 2020 20:26

IN BRIEF: Cambridge Cognition Interim Order Intake Surges Annually

IN BRIEF: Cambridge Cognition Interim Order Intake Surges Annually

Read more
30 Jun 2020 11:00

Cambridge Cognition order intake nearly doubles in H1

(Sharecast News) - Software group Cambridge Cognition has seen its order intake almost double in the six months ended 30 June following the company's switch in focus to having a more diversified portfolio and its efforts to commercialise new products.

Read more
27 May 2020 13:10

UK TRADING UPDATE SUMMARY: Caffyns To Reopen Showrooms As Curbs Ease

UK TRADING UPDATE SUMMARY: Caffyns To Reopen Showrooms As Curbs Ease

Read more
27 May 2020 10:08

Cambridge Cognition inks multiple new contracts for virtual trials

(Sharecast News) - Digital brain health products developer Cambridge Cognition has secured several new contracts to support pharmaceutical clients in delivering virtual clinical trials, including two contracts collectively worth over £1m.

Read more
5 May 2020 12:11

Cambridge Cognition 2019 Loss Widens As Revenue Falls On Sales Decline

Cambridge Cognition 2019 Loss Widens As Revenue Falls On Sales Decline

Read more
17 Mar 2020 16:03

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
17 Mar 2020 16:02

Cambridge Cognition Three Contracts Worth Total Of GBP1.4 Million

Cambridge Cognition Three Contracts Worth Total Of GBP1.4 Million

Read more
2 Mar 2020 16:00

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
19 Feb 2020 09:40

Cambridge Cognition To Raise GBP1.4 Million; Expects Wider Annual Loss

Cambridge Cognition To Raise GBP1.4 Million; Expects Wider Annual Loss

Read more
19 Feb 2020 08:03

Cambridge Cognition losses widen amid sales slump

(Sharecast News) - Digital solutions development group Cambridge Cognition warned on Wednesday that its full-year losses were set to widen after the lower level of sales seen throughout the first half of the year extended into the third quarter

Read more
25 Nov 2019 09:36

Cambridge Cognition gains client with improved electronic assessment platform

(Sharecast News) - Brain health solutions developer Cambridge Cognition Holdings announced the launch of an improved electronic clinical outcomes assessment ('eCOA') platform on Monday, claiming it had already attracted a new client from one of the world's top 10 pharmaceutical companies.

Read more
25 Oct 2019 15:22

Cambridge Cognition hoping to ride coat-tails of Biogen Alzheimer's programme

(Sharecast News) - Cambridge Cognition announced on Friday that, Following a consultation with the US Food and Drug Administration (FDA), Biogen and Eisai have announced plans to pursue regulatory approval for 'aducanumab', which would be the first therapy to tackle clinical decline in early Alzheimer's disease.

Read more
25 Oct 2019 10:37

Cambridge Cognition Senses Opportunity In Biogen's Alzheimer Drug Push

Cambridge Cognition Senses Opportunity In Biogen's Alzheimer Drug Push

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.